Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study

BACKGROUND: Sandoz etanercept (SDZ ETN; GP2015) is an etanercept biosimilar with equivalent efficacy and comparable safety and immunogenicity to reference etanercept (ETN) in patients with moderate-to-severe chronic plaque-type psoriasis. METHODS: EQUIRA was a phase III, double-blind study conducted...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Arthritis Res Ther
Главные авторы: Jaworski, Janusz, Matucci-Cerinic, Marco, Schulze-Koops, Hendrik, Buch, Maya H., Kucharz, Eugeniusz J., Allanore, Yannick, Kavanaugh, Arthur, Young, Philip, Babic, Goran
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6540397/
https://ncbi.nlm.nih.gov/pubmed/31138316
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-019-1907-x
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы